Press Releases

Biofidelity is proud to have been selected as a grant recipient by the Green Business Impact Programme, a collaborative effort led by Cambridge City Council, South Cambridgeshire District Council, Huntingdonshire District Council, the Cambridgeshire and Peterborough Growth Hub and the Cambridgeshire & Peterborough Combined Authority and administered by Allia Impact, Ltd.

Biofidelity announced the publication of data that highlights how Aspyre® technology addresses the urgent need for rapid, accessible molecular diagnostics informing actionable genomic variants in cancer.

Biofidelity today announced the launch of Aspyre Clinical Test for Lung for liquid biopsy samples. Aspyre Clinical Test for Lung analyzes all guideline-recommended genes for non-small cell lung cancer (NSCLC) patients in both DNA and RNA from tissue and blood within two days, benefitting patients by enabling earlier treatment decisions.

Biofidelity, a leader in innovative genomic solutions, today announced the launch of Aspyre Lung Reagents (research use only) for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer (NSCLC) biomarkers in both DNA and RNA from tissue and blood.

Lee Anderson joins Biofidelity to expand the adoption of Aspyre Lung, a completely new category of molecular diagnostic that fulfills an acute unmet clinical need for people with non-small cell lung cancer and the clinicians who treat them.

Biofidelity, a leader in innovative genomic solutions, is proud to announce the establishment of a manufacturing facility dedicated to genomic assay production in the UK.

Biofidelity, a revolutionary genomic technology company, today announced the appointments of Dr. Kelly Ray Pitts, PhD, as Chief Operating Officer, Catherine Jean Potgieter, FCIPD, as Vice President of People and Dr. Jonathan Senior, MD, as Chief Financial Officer.

Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, announced that new data from its breakthrough product Aspyre Lung will be presented in three scientific posters.

Biofidelity successfully completed a financing round totaling $24 million bringing total funding raised since the Company was founded in 2019 to $60 million.

Biofidelity and Fidelis Sustainability Distribution (Fidelis) today announced that they have entered into an agreement to make Aspyre® Lung available to VA Medical Centers and active military institutions across the US.

Biofidelity today announced the commercial launch of its Aspyre® Lung Reagents product. Aspyre Lung dramatically simplifies and accelerates the detection of genomic biomarkers, enabling localized testing at a fraction of the cost of current sequencing tests, with results available in days instead of weeks.

Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, today announced the commercial launch of Aspyre® Lung in the US.

Biofidelity, a revolutionary genomic technology company, announced that an abstract of data from its breakthrough ASPYRE® technology will be shared at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting

Biofidelity, a revolutionary genomic technology company, has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director effective immediately.

Biofidelity, a revolutionary genomic technology company, announced that new data from its breakthrough Aspyre® technology will be presented in a scientific poster at the upcoming Association for Molecular Pathology 2022 Annual Meeting.

Biofidelity, a revolutionary genomic technology company, has developed a low-cost, simple and rapid assay for single-molecule detection of multiple gene fusions from RNA.

Biofidelity, a revolutionary genomic technology company dedicated to unleashing the potential of genomics to transform human health and the world we live in, announced today the issuance of several new patents.

Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors.

Biofidelity, a pioneer in precision cancer diagnostics, has expanded its Scientific Advisory Board to include Lee N. Newcomer, MD, an oncologist and seasoned healthcare executive.

Biofidelity, a pioneer in precision cancer diagnostics, today praised California Governor Gavin Newsom and the California legislature for the October 6th passage of SB 535.

Biofidelity Ltd, the cancer diagnostics company, today announced the successful completion of alpha testing of its new Aspyre Lung reagents at multiple laboratory locations in the US and UK.  

Biofidelity Ltd, the cancer diagnostics company, today announces the opening of its US headquarters in Research Triangle Park, North Carolina, expanding its presence in the key US market ahead of its first product launch later this year.

Biofidelity Ltd, the cancer diagnostics company, today announces the members of its newly-formed Scientific Advisory Board (SAB) with the appointments of leaders from the clinical, pharmaceutical and patient advocacy fields.

Cambridge-based cancer diagnostics company Biofidelity has been granted a key patent in the US protecting its underlying technology and is expecting to launch its first product later this year.

Biofidelity Ltd, the cancer diagnostics company, today announced that it has been granted a key patent in the US protecting its underlying technology.

Biofidelity Ltd, the cancer diagnostics company, today announces that the first peer review article detailing its novel Aspyre™ technology has been published in Scientific Reports, a Nature journal.

Biofidelity Ltd, the cancer diagnostics company, today announces the appointment of Wendy J. Levin MD MS as Chief Medical Officer, based in the US.

Biofidelity Ltd, the cancer diagnostics company, today announces the further expansion of its leadership team with the appointment of Dr. Robert Osborne as Chief Operating Officer.

Biofidelity Ltd, the cancer diagnostics company, today announced the opening of its new headquarters as it continues its significant recruitment ahead of commercialization of its first products.

Biofidelity Ltd, the cancer diagnostics company, today announces the appointment of Stephen Miller as Chief Commercial Officer, based in the US.

Biofidelity Ltd, the cancer diagnostics company, today announces the appointment of Dr. Heiner Dreismann, former President and CEO of Roche Molecular Systems, as Chairman with immediate effect.

Biofidelity Ltd, the cancer diagnostics company, today announces the successful completion of a $12m Series A financing.

Our goal is to improve patient outcomes in oncology by enabling much greater access to the highest precision diagnostic tests. This collaboration with Agilent in lung cancer has again demonstrated that Biofidelity’s molecular assays dramatically increase the effectiveness and speed of diagnosis, supporting early detection of disease, better targeting of […]

Biofidelity Ltd, a company providing advanced molecular assays for the sensitive detection of low-frequency genetic mutations, today announces it has received £500,000 in grant funding from Innovate UK, the UK’s Innovation Agency.

Biofidelity Ltd, the cancer diagnostics company, today announces the appointment of Dr. Heiner Dreismann, former President and CEO of Roche Molecular Systems, as Chairman.